{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:54Z","timestamp":1740147774737,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11899-022-00669-1","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T07:05:22Z","timestamp":1661843122000},"page":"206-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Value in Myeloma Care: Myth or Reality"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-0186","authenticated-orcid":false,"given":"Evguenia","family":"Ouchveridze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"issue":"17","key":"669_CR1","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928\u201337.","journal-title":"J Clin Oncol"},{"key":"669_CR2","unstructured":"Cavallo J Defining cure in multiple myeloma: a conversation with S. Vincent Rajkumar.\u00a02021. Available from: https:\/\/ascopost.com\/issues\/july-10-2021\/defining-cure-in-multiple-myeloma\/.\u00a0Accessed 17 May 2022."},{"issue":"4","key":"669_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-022-00671-z","volume":"12","author":"E Ouchveridze","year":"2022","unstructured":"Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, et al. Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J. 2022;12(4):74.","journal-title":"Blood Cancer J"},{"issue":"9","key":"669_CR4","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","volume":"103","author":"S Thorsteinsdottir","year":"2018","unstructured":"Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018;103(9):e412\u2013e5.","journal-title":"Haematologica."},{"issue":"5","key":"669_CR5","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521\u20136.","journal-title":"Blood."},{"issue":"7","key":"669_CR6","doi-asserted-by":"publisher","first-page":"e2116357","DOI":"10.1001\/jamanetworkopen.2021.16357","volume":"4","author":"K Bhattacharya","year":"2021","unstructured":"Bhattacharya K, Bentley JP, Ramachandran S, Chang Y, Banahan BF 3rd, Shah R, et al. Phase-specific and lifetime costs of multiple myeloma among older adults in the US. JAMA Netw Open. 2021;4(7):e2116357.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"669_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-020-0338-x","volume":"10","author":"RS Vincent","year":"2020","unstructured":"Vincent RS. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10(6):71.","journal-title":"Blood Cancer J"},{"key":"669_CR8","unstructured":"Prices of Drugs from drugs.com [Available from: https:\/\/www.drugs.com\/price-guide\/."},{"key":"669_CR9","unstructured":"Medicare Part B Drug and Biological Average Sales Price: 2017 ASP Drug Pricing Files.\u00a02017.\u00a0https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Part-B-Drugs\/McrPartBDrugAvgSalesPrice. Accessed 9 July 2022."},{"key":"669_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/EDBK_200867","volume":"38","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV. Value and cost of myeloma therapy. Am Soc Clin Oncol Educ Book. 2018;38:662\u20136.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"669_CR11","unstructured":"SEER. SEER Cancer Stat Facts [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"669_CR12","doi-asserted-by":"crossref","unstructured":"Dusetzina SB. Your money or your life \u2014 the high cost of cancer drugs under Medicare Part D. New England JMed 2022.","DOI":"10.1056\/NEJMp2202726"},{"issue":"9","key":"669_CR13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844\u201353.","journal-title":"JAMA."},{"issue":"11","key":"669_CR14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","volume":"177","author":"V Prasad","year":"2017","unstructured":"Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177(11):1569\u201375.","journal-title":"JAMA Intern Med"},{"key":"669_CR15","unstructured":"CMS Drug Pricing. Available from: https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2020-asp-drug-pricing-files."},{"key":"669_CR16","unstructured":"What\u2019s the latest on medicare drug price negotiations? Available from: https:\/\/www.kff.org\/medicare\/issue-brief\/whats-the-latest-on-medicare-drug-price-negotiations\/."},{"key":"669_CR17","first-page":"100332","volume":"21","author":"B Gyawali","year":"2020","unstructured":"Gyawali B, Hey SP, Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs. E Clin Med. 2020;21:100332.","journal-title":"E Clin Med"},{"issue":"6","key":"669_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ajh.26166","volume":"96","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Koehn K, Abdallah AO, Sborov W, Rajkumar D, Kumar SV, Mc Clune B, et al. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review. Am J Hematol. 2021;96(6):690\u20137.","journal-title":"Am J Hematol"},{"issue":"12","key":"669_CR19","doi-asserted-by":"publisher","first-page":"e892","DOI":"10.1016\/S2352-3026(20)30292-1","volume":"7","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Cannella L, Cottone F, Efficace F. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. Lancet Haematol. 2020;7(12):e892\u2013901.","journal-title":"Lancet Haematol"},{"key":"669_CR20","unstructured":"Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, et al. Minimal residual disease in myeloma: application for clinical care and new drug registration. Clin Cancer Res. 2021."},{"issue":"4","key":"669_CR21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","volume":"6","author":"M Delforge","year":"2022","unstructured":"Delforge M, Shah N, Miguel JSF, Braverman J, Dhanda DS, Shi L, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6(4):1309\u201318.","journal-title":"Blood Adv"},{"issue":"4","key":"669_CR22","doi-asserted-by":"publisher","first-page":"e218084","DOI":"10.1001\/jamanetworkopen.2021.8084","volume":"4","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V. Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review. JAMA Netw Open. 2021;4(4):e218084.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"669_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41571-021-00581-2","volume":"19","author":"GR Mohyuddin","year":"2022","unstructured":"Mohyuddin GR, Mian H. Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nat Rev Clin Oncol. 2022;19(1):3\u20134.","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"669_CR24","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMp1011024","volume":"363","author":"ME Porter","year":"2010","unstructured":"Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"669_CR25","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1097\/HS9.0000000000000366","volume":"4","author":"S Oerlemans","year":"2020","unstructured":"Oerlemans S, Bennink MC, Levin MD, Broijl A, Van der Klift M, Van Deursen J, et al. Development of a patient centered outcome set for patients with multiple myeloma to be used in clinical practice. Hemasphere. 2020;4(3):e366.","journal-title":"Hemasphere."},{"issue":"7","key":"669_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","volume":"30","author":"J Witte","year":"2019","unstructured":"Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol. 2019;30(7):1061\u201370.","journal-title":"Ann Oncol"},{"issue":"10","key":"669_CR27","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","volume":"2","author":"SF Huntington","year":"2015","unstructured":"Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2(10):e408\u201316.","journal-title":"Lancet Haematol"},{"key":"669_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2021.12.037","volume":"167","author":"W Wesson","year":"2022","unstructured":"Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, et al. Characteristics of clinical trials for haematological malignancies from 2015 to 2020: a systematic review. Eur J Cancer. 2022;167:152\u201360.","journal-title":"Eur J Cancer"},{"issue":"10040","key":"669_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0140-6736(16)30954-0","volume":"388","author":"P Moreau","year":"2016","unstructured":"Moreau P, Rajkumar SV. Multiple myeloma--translation of trial results into reality. Lancet. 2016;388(10040):111\u20133.","journal-title":"Lancet."},{"issue":"4","key":"669_CR30","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1016\/S2352-3026(21)00024-7","volume":"8","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, et al. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol. 2021;8(4):e299\u2013304.","journal-title":"Lancet Haematol"},{"key":"669_CR31","unstructured":"Unprecedented outcomes of Isatuximab [press release]."},{"issue":"12","key":"669_CR32","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s40273-016-0434-8","volume":"34","author":"F Antonanzas","year":"2016","unstructured":"Antonanzas F, Terkola R, Postma M. The value of medicines: a crucial but vague concept. Pharmacoeconomics. 2016;34(12):1227\u201339.","journal-title":"Pharmacoeconomics."},{"issue":"8","key":"669_CR33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.mayocp.2015.06.001","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996\u20131000.","journal-title":"Mayo Clin Proc"},{"key":"669_CR34","unstructured":"How a drugmaker gamed the system to keep generic competition away."},{"issue":"22","key":"669_CR35","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315.","journal-title":"N Engl J Med"},{"issue":"6","key":"669_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41571-019-0198-0","volume":"16","author":"P Kapoor","year":"2019","unstructured":"Kapoor P, Rajkumar SV. MAIA under the microscope - bringing trial design into focus. Nat Rev Clin Oncol. 2019;16(6):339\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"15_suppl","key":"669_CR37","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2021.39.15_suppl.8004","volume":"39","author":"P Moreau","year":"2021","unstructured":"Moreau P, Sonneveld P, Investigators ftCS. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol. 2021;39(15_suppl):8004.","journal-title":"J Clin Oncol"},{"issue":"23","key":"669_CR38","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988\u201399.","journal-title":"Blood Adv"},{"issue":"1","key":"669_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","volume":"35","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35(1):18\u201330.","journal-title":"Leukemia."},{"key":"669_CR40","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2021 JCO2101935."},{"issue":"3","key":"669_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjh.14065","volume":"174","author":"A Ray","year":"2016","unstructured":"Ray A, Ravillah D, Das DS, Song Y, Nordstrom E, Gullbo J, et al. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016;174(3):397\u2013409.","journal-title":"Br J Haematol"},{"key":"669_CR42","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.tranon.2022.101374","volume":"18","author":"T Olivier","year":"2022","unstructured":"Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Transl Oncol. 2022;18:101374.","journal-title":"Transl Oncol"},{"issue":"23","key":"669_CR43","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1001\/jama.2015.12206","volume":"314","author":"S Ehrhardt","year":"2015","unstructured":"Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health funding for clinical trials registered in ClinicalTrials.gov. JAMA. 2015;314(23):2566\u20137.","journal-title":"JAMA."},{"issue":"3","key":"669_CR44","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1001\/jamainternmed.2015.7805","volume":"176","author":"MV Abola","year":"2016","unstructured":"Abola MV, Prasad V. Characteristics and conflicts of public speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. JAMA Intern Med. 2016;176(3):389\u201391.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"669_CR45","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jamaoncol.2018.3738","volume":"4","author":"C Wayant","year":"2018","unstructured":"Wayant C, Turner E, Meyer C, Sinnett P, Vassar M. Financial conflicts of interest among oncologist authors of reports of clinical drug trials. JAMA Oncol. 2018;4(10):1426\u20138.","journal-title":"JAMA Oncol"},{"issue":"2","key":"669_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ihj.2016.03.011","volume":"68","author":"S Mishra","year":"2016","unstructured":"Mishra S. Do medical conferences have a role to play? Sharpen the saw. Indian Heart J. 2016;68(2):111\u20133.","journal-title":"Indian Heart J"},{"issue":"12","key":"669_CR47","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1007\/s00520-020-05406-z","volume":"28","author":"KA Fischer","year":"2020","unstructured":"Fischer KA, Walling A, Wenger N, Glaspy J. Cost health literacy as a physician skill-set: the relationship between oncologist reported knowledge and engagement with patients on financial toxicity. Support Care Cancer. 2020;28(12):5709\u201315.","journal-title":"Support Care Cancer"},{"issue":"3","key":"669_CR48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jamainternmed.2016.8467","volume":"177","author":"DL Tao","year":"2017","unstructured":"Tao DL, Boothby A, McLouth J, Prasad V. Financial conflicts of interest among hematologist-oncologists on Twitter. JAMA Intern Med. 2017;177(3):425\u20137.","journal-title":"JAMA Intern Med"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00669-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-022-00669-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00669-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T05:08:30Z","timestamp":1669871310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-022-00669-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1007\/s11899-022-00669-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"11 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}